RNA-based Therapeutics and Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
177 Pages
February 2024
Region: Global
Fairfield Market Research
ID: 5938852

Revolutionizing Healthcare: RNA-Based Therapeutics and Vaccines Market Poised for Stratospheric Growth

The global RNA-based therapeutics and vaccines market experienced remarkable growth rates from 2019 to 2023 and is projected to continue its upward trajectory. By 2024, it is anticipated to reach a substantial value and is forecasted to grow significantly by 2031.

Unprecedented Growth Trajectory

The global RNA-based therapeutics and vaccines market, valued at US$ 10 Mn in 2024 is primed for an exponential six-fold growth by 2031. This evolution is fueled by groundbreaking advancements in RNA technology, particularly in mRNA-based treatments that have demonstrated efficacy in combating a wide array of diseases, including the formidable challenges posed by the Covid-19 pandemic.

Unlocking the Power of RNA

RNA therapeutics encompass RNA aptamers, RNA interference (RNAi), antisense RNA (asRNA), and messenger RNA (mRNA). Among these, mRNA-based therapy stands out for its unique ability to trigger protein synthesis within cells, making it pivotal in vaccine development.

The Oncology Frontier

With nearly 35% of RNA therapeutic developments focused on oncology, it is evident that cancer treatment stands at the forefront of innovation in this domain. RNA-based biopharmaceuticals offer a refined approach to tackling rare and chronic diseases, including cancer, tuberculosis, diabetes, and cardiovascular ailments.

Global Expansion and Market Dynamics

North America and Europe lead the charge, jointly expected to be worth US$ 53.07 Mn in 2024. However, the Asia-Pacific region is rapidly gaining traction, with increasing awareness and substantial investments driving market growth.

Overcoming Challenges

While RNA therapeutics offer unparalleled stability and efficacy, the high cost of research and the inherent risks of clinical trials remain significant challenges. Additionally, ensuring optimal drug delivery presents a persistent hurdle in realizing the full potential of RNA-based treatments.

Innovative Solutions and Collaborations

Manufacturers are leveraging RNA therapeutics' stability to develop novel treatments, with technologies such as Smart technology, antisense technology, and RNA interference technology leading the charge. Collaborations, such as Pfizer's recent agreement with Acuitas Therapeutics, underscore the industry's commitment to innovation and expansion.

Covid-19: A Catalyst for Innovation

The Covid-19 pandemic has further accelerated research and development efforts in RNA-based therapeutics and vaccines. With the emergence of variants like Omicron, combating infectious diseases has become an urgent global imperative, further underscoring the importance of RNA-based solutions.

A Bright Future Ahead

As the healthcare landscape continues to evolve, RNA-based therapeutics and vaccines promise to revolutionize disease management and prevention. With relentless innovation, strategic partnerships, and a steadfast commitment to advancing medical science, the future of healthcare looks brighter than ever before.

Competitive Analysis

Key Companies of Market Are:

Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma Corp.
Arrowhead Pharmaceuticals, Inc.
BioNTech AG
CureVac AG
Dicerna Pharmaceuticals, Inc.
Regulus Therapeutics, Inc.
Marina Biotech, Inc.
miRagen Therapeutics
Moderna Therapeutics, Inc.
Quark Pharmaceuticals, Inc.
Santaris Pharma A/S (A Roche Company)
Sylentis S.A.

Key Segments Covered in RNA-based Therapeutics and Vaccines Market

RNA-based Therapeutics and Vaccines Market by Type of Product

Workstations
Reagents and Consumables
Kits (RNA sample preparation and DNA sample preparation)

RNA-based Therapeutics and Vaccines Market by Application

Research Applications
Diagnostic Testing
Clinical Testing

RNA-based Therapeutics and Vaccines Market by End User

Diagnostic Centers
Hospitals
Academic & Research Institutes
Forensic Science Laboratories
CROs (Contract Research Organizations)

RNA-based Therapeutics and Vaccines Market by Region

North America RNA-based Therapeutics and Vaccines Market
Latin America RNA-based Therapeutics and Vaccines Market
Europe RNA-based Therapeutics and Vaccines Market
Asia-Pacific RNA-based Therapeutics and Vaccines Market
Middle East & Africa (MEA) RNA-based Therapeutics and Vaccines Market

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global RNA-based Therapeutics and Vaccines Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global RNA-based Therapeutics and Vaccines Market Outlook, 2018 - 2031

3.1. Global RNA-based Therapeutics and Vaccines Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. RNA-based Therapeutics
3.1.1.1.1. siRNA
3.1.1.1.2. miRNA
3.1.1.2. RNA-based Vaccines
3.1.1.2.1. mRNA
3.2. Global RNA-based Therapeutics and Vaccines Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Oncology
3.2.1.2. Immunology
3.2.1.3. Ophthalmology
3.2.1.4. Cardiovascular Diseases
3.2.1.5. Infectious Diseases
3.2.1.6. Genetic Diseases
3.2.1.7. Others
3.3. Global RNA-based Therapeutics and Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Diagnostic Centers
3.3.1.2. Hospitals
3.3.1.3. Academic & Research Institutes
3.3.1.4. Forensic Science Laboratories
3.3.1.5. CROs (Contract Research Organizations)
3.4. Global RNA-based Therapeutics and Vaccines Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America RNA-based Therapeutics and Vaccines Market Outlook, 2018 - 2031

4.1. North America RNA-based Therapeutics and Vaccines Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. RNA-based Therapeutics
4.1.1.1.1. siRNA
4.1.1.1.2. miRNA
4.1.1.2. RNA-based Vaccines
4.1.1.2.1. mRNA
4.2. North America RNA-based Therapeutics and Vaccines Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Oncology
4.2.1.2. Immunology
4.2.1.3. Ophthalmology
4.2.1.4. Cardiovascular Diseases
4.2.1.5. Infectious Diseases
4.2.1.6. Genetic Diseases
4.2.1.7. Others
4.3. North America RNA-based Therapeutics and Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Diagnostic Centers
4.3.1.2. Hospitals
4.3.1.3. Academic & Research Institutes
4.3.1.4. Forensic Science Laboratories
4.3.1.5. CROs (Contract Research Organizations)
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America RNA-based Therapeutics and Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe RNA-based Therapeutics and Vaccines Market Outlook, 2018 - 2031

5.1. Europe RNA-based Therapeutics and Vaccines Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. RNA-based Therapeutics
5.1.1.1.1. siRNA
5.1.1.1.2. miRNA
5.1.1.2. RNA-based Vaccines
5.1.1.2.1. mRNA
5.2. Europe RNA-based Therapeutics and Vaccines Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Oncology
5.2.1.2. Immunology
5.2.1.3. Ophthalmology
5.2.1.4. Cardiovascular Diseases
5.2.1.5. Infectious Diseases
5.2.1.6. Genetic Diseases
5.2.1.7. Others
5.3. Europe RNA-based Therapeutics and Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Diagnostic Centers
5.3.1.2. Hospitals
5.3.1.3. Academic & Research Institutes
5.3.1.4. Forensic Science Laboratories
5.3.1.5. CROs (Contract Research Organizations)
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe RNA-based Therapeutics and Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.7. France RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.8. France RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.9. France RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest of Europe RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest of Europe RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest of Europe RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific RNA-based Therapeutics and Vaccines Market Outlook, 2018 - 2031

6.1. Asia Pacific RNA-based Therapeutics and Vaccines Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. RNA-based Therapeutics
6.1.1.1.1. siRNA
6.1.1.1.2. miRNA
6.1.1.2. RNA-based Vaccines
6.1.1.2.1. mRNA
6.2. Asia Pacific RNA-based Therapeutics and Vaccines Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Oncology
6.2.1.2. Immunology
6.2.1.3. Ophthalmology
6.2.1.4. Cardiovascular Diseases
6.2.1.5. Infectious Diseases
6.2.1.6. Genetic Diseases
6.2.1.7. Others
6.3. Asia Pacific RNA-based Therapeutics and Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Diagnostic Centers
6.3.1.2. Hospitals
6.3.1.3. Academic & Research Institutes
6.3.1.4. Forensic Science Laboratories
6.3.1.5. CROs (Contract Research Organizations)
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific RNA-based Therapeutics and Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
6.4.1.2. China RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.3. China RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.10. India RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
6.4.1.11. India RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.12. India RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America RNA-based Therapeutics and Vaccines Market Outlook, 2018 - 2031

7.1. Latin America RNA-based Therapeutics and Vaccines Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. RNA-based Therapeutics
7.1.1.1.1. siRNA
7.1.1.1.2. miRNA
7.1.1.2. RNA-based Vaccines
7.1.1.2.1. mRNA
7.2. Latin America RNA-based Therapeutics and Vaccines Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Oncology
7.2.1.2. Immunology
7.2.1.3. Ophthalmology
7.2.1.4. Cardiovascular Diseases
7.2.1.5. Infectious Diseases
7.2.1.6. Genetic Diseases
7.2.1.7. Others
7.3. Latin America RNA-based Therapeutics and Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Diagnostic Centers
7.3.1.2. Hospitals
7.3.1.3. Academic & Research Institutes
7.3.1.4. Forensic Science Laboratories
7.3.1.5. CROs (Contract Research Organizations)
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America RNA-based Therapeutics and Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest of Latin America RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest of Latin America RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest of Latin America RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa RNA-based Therapeutics and Vaccines Market Outlook, 2018 - 2031

8.1. Middle East & Africa RNA-based Therapeutics and Vaccines Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. RNA-based Therapeutics
8.1.1.1.1. siRNA
8.1.1.1.2. miRNA
8.1.1.2. RNA-based Vaccines
8.1.1.2.1. mRNA
8.2. Middle East & Africa RNA-based Therapeutics and Vaccines Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Oncology
8.2.1.2. Immunology
8.2.1.3. Ophthalmology
8.2.1.4. Cardiovascular Diseases
8.2.1.5. Infectious Diseases
8.2.1.6. Genetic Diseases
8.2.1.7. Others
8.3. Middle East & Africa RNA-based Therapeutics and Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Diagnostic Centers
8.3.1.2. Hospitals
8.3.1.3. Academic & Research Institutes
8.3.1.4. Forensic Science Laboratories
8.3.1.5. CROs (Contract Research Organizations)
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa RNA-based Therapeutics and Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa RNA-based Therapeutics and Vaccines Market by Product Type, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa RNA-based Therapeutics and Vaccines Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa RNA-based Therapeutics and Vaccines Market by End User, Value (US$ Mn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By End User vs By Application Heat map
9.2. Manufacturer vs by Indication Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Alnylam Pharmaceuticals, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Arbutus Biopharma Corp.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Arrowhead Pharmaceuticals, Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. BioNTech AG
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. CureVac AG
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Dicerna Pharmaceuticals, Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Regulus Therapeutics, Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Marina Biotech, Inc
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. miRagen Therapeutics
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Moderna Therapeutics, Inc
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Quark Pharmaceuticals, Inc.
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Santaris Pharma A/S (A Roche Company)
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Sylentis S.A.
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma Corp.
Arrowhead Pharmaceuticals, Inc.
BioNTech AG
CureVac AG
Dicerna Pharmaceuticals, Inc.
Regulus Therapeutics, Inc.
Marina Biotech, Inc.
miRagen Therapeutics
Moderna Therapeutics, Inc.
Quark Pharmaceuticals, Inc.
Santaris Pharma A/S (A Roche Company)
Sylentis S.A.

Methodology

LOADING...